Sort
53,477 grants matching “addiction”
CTN HEAL ENHANCEMENT. CLINICAL COORDINATING CENTER FOR NIDA'S CLINICAL TRIALS NETWORK. TO2. POP: 8/15/24 - 11/1/2026
$2,988,430Eve Jelstrom · The Emmes Company, Llc · N01 · FY2024 · DA
Center for Genetic Studies of Drug Abuse in Outbred Rats
$2,985,563Abraham A Palmer · University Of California, San Diego · P50 · FY2020 · DA
Center for Adolescent Reward, Rhythms and Sleep (CARRS)
$2,983,571Colleen A McClung · University Of Pittsburgh At Pittsburgh · P50 · FY2024 · DA
Center for Adolescent Reward, Rhythms and Sleep (CARRS)
$2,982,653Colleen A McClung · University Of Pittsburgh At Pittsburgh · P50 · FY2023 · DA
Center for Adolescent Reward, Rhythms and Sleep (CARRS)
$2,982,281Colleen A McClung · University Of Pittsburgh At Pittsburgh · P50 · FY2022 · DA
Novel Medication Approaches for Substance Abuse
$2,972,692Herbert David Kleber · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · P50 · FY2007 · DA
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
$2,972,035Lorenzo Leggio · National Institute On Drug Abuse · ZIA · FY2023 · DA
Novel Medication Approaches for Substance Abuse
$2,971,695New York State Psychiatric Institute · P50 · FY2005 · DA
Neurotoxicity in the adult rat following chronic exposure to methamphetamine
$2,968,221Jean Lud Cadet · National Institute On Drug Abuse · ZIA · FY2022 · DA
Role of coordinated multi-area reactivations during transitions between automatic and flexible behaviors.
$2,965,125Karunesh Ganguly · University Of California, San Francisco · RF1 · FY2023 · NS
Helping to End Addiction Long-term (HEAL): Probe/Drug Lead Production
$2,964,594Matthew Hall · National Center For Advancing Translational Sciences · ZIA · FY2021 · TR
Lead Optimization and Preclinical Development of Human Nicotine-Specific mAbs
$2,960,853Matthew W Kalnik · Antidote Therapeutics, Inc. · R01 · FY2015 · DA
Opiod Analgesic Reduction Study (OARS): Managing Acute Post-Operative Surgical Pain
$2,960,004Cecile Feldman · Rutgers Biomedical And Health Sciences · UH3 · FY2022 · DE
Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome
$2,959,252Martha J Morrell · Neuropace, Inc. · UH3 · FY2023 · NS
EPPIC-NET DCC
$2,959,226Eva Petkova · New York University School Of Medicine · U24 · FY2020 · NS
Florida Node of The Drug Abuse Clinical Trials Network
$2,956,847Jose Szapocznik · University Of Miami School Of Medicine · U10 · FY2006 · DA
Clinical Genomics and Experimental Therapeutics
$2,956,797Falk Lohoff · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2019 · AA
Illuminating neural coding mechanisms using in vivo calcium imaging in freely behaving rodents
$2,955,121Da-Ting Lin · National Institute On Drug Abuse · ZIA · FY2024 · DA
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
$2,953,770Lorenzo Leggio · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2017 · AA
The National Drug Abuse Treatment Clinical Trials Network
$2,953,306Walter Nmn Ling · University Of California Los Angeles · U10 · FY2015 · DA
HEAL Accelerator: Leveraging Partnerships and Targeted Dissemination to Advance Uptake
$2,953,243Faye S Taxman · George Mason University · OT2 · FY2023 · OD
Neural circuit dynamics of drug action
$2,951,526Karl Alexander Deisseroth · Stanford University · P50 · FY2017 · DA
Neurobiology Of Relapse To Opiate and Psychostimulant Drugs
$2,949,353Yavin Shaham · National Institute On Drug Abuse · ZIA · FY2022 · DA
Center for Genetic Studies of Drug Abuse in Outbred Rats
$2,949,105Abraham A Palmer · University Of California, San Diego · P50 · FY2019 · DA
PF614 MPAR Abuse Deterrent opioid prodrug with overdose protection: Pre-Clinical Development and Phase 1 Clinical Trial
$2,949,024Lynn Kirkpatrick · Ensysce Biosciences, Inc. · UG3 · FY2019 · DA